Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis

Clinical and Experimental Rheumatology

Volumn 24, Issue 6 SUPPL. 43, 2006, Pages

  Mukhtyar, Chetan ^a   Hellmich, Bernhard ^b   Jayne, David ^c   Flossmann, Oliver ^c   Luqmani, Raashid ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Antibodies; Antineutrophil cytoplasmic; Churg Strauss syndrome; Outcome assessment (health care); Recurrence; Remission induction; Severity of illness index; Wegener's granulomatosis

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLACEBO; PREDNISOLONE; RITUXIMAB;

ANCA ASSOCIATED VASCULITIS; ANTIBODY DETECTION; ARTICLE; CHURG STRAUSS SYNDROME; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DIALYSIS; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE SEVERITY; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LOW DRUG DOSE; MAINTENANCE THERAPY; META ANALYSIS; NOMENCLATURE; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; REMISSION; RHEUMATOID ARTHRITIS; STANDARDIZATION; SYSTEMATIC REVIEW; SYSTEMIC VASCULITIS; TREATMENT PLANNING; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ENDPOINT DETERMINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION; REMISSION, SPONTANEOUS; SEVERITY OF ILLNESS INDEX; VASCULITIS;

EID: 33750732322     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. WALTON EW: Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958; (5091): 265-70.
2. FAUCI AS, HAYNES BF, KATZ P, WOLFF SM: Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76-85.
3. KOUTANTJI M, HARROLD E, LANE SE, PEARCE S, WATTS RA, SCOTT DG: Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. Arthritis Rheum 2003; 49: 826-37.
4. HOFFMAN GS, DRUCKER Y, COTCH MF, LOCKER GA, EASLEY K, KWOH K: Wegener's granulomatosis: patient-reported effects of disease on health, function, and income. Arthritis Rheum 1998; 41: 2257-62.
5. BOOMSMA MM, STEGEMAN CA, TERVAERT JW: Comparison of Dutch and US patients' perceptions of the effects of Wegener's granulomatosis on health, function, income, and interpersonal relationships: comment on the article by Hoffman et al. Arthritis Rheum 1999; 42: 2495-7.
6. MCHORNEY CA, WARE JE Jr, ROGERS W, RACZEK AE, LU JF: The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study. Med Care 1992; 30 (5 Suppl.): MS253-65.
7. JAYNE D, RASMUSSEN N, ANDRASSY K et al.: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44.
8. DE GROOT K, RASMUSSEN N, BACON PA et al.: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 2461-9.
9. HOFFMAN GS, KERR GS, LEAVITT RY et al.: Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98.
10. REINHOLD-KELLER E, BEUGE N, LATZA U et al: An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 1021-32.
11. SEO P, MIN YI, HOLBROOK JT et al.: Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005; 52: 2168-78.
12. GUILLEVIN L, LHOTE F, COHEN P et al.: Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum 1995; 38: 1638-45.
13. GAYRAUD M, GUILLEVIN L, COHEN P et al.: Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 1997; 36: 1290-7.
14. ROTTEM M, FAUCI AS, HALLAHAN CW et al.: Wegener granulomatosis in children and adolescents: clinical presentation and outcome. J Pediatr 1993; 122: 26-31.
15. AASAROD K, IVERSEN BM, HAMMERSTROM J, BOSTAD L, VATTEN L, JORSTAD S: Wegener's granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 2000; 15: 611-8.
16. KOLDINGSNES W, NOSSENT JC: Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis. J Rheumatol 2003; 30: 80-8.
17. GUILLEVIN L, COHEN P, GAYRAUD M, LHOTE F, JARROUSSE B, CASASSUS P: Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78: 26-37.
18. HOGAN SL, FALK RJ, CHIN H et al.: Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005; 143: 621-31.
19. RIHOVA Z, JANCOVA E, MERTA M et al.: Long-term outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis with renal involvement. Kidney Blood Press Res 2005; 28: 144-52.
20. HELLMICH B, FLOSSMANN O, BACON P et al.: EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on ANCA-associated vasculitis. Ann Rheum Dis. In press.
21. LUQMANI RA, BACON PA, MOOTS RJ et al.: Birmingham Vascultis Activity Score (BVAS) in systemic necrotizing vasculitis. Qjm 1994; 87: 671-8.
22. STONE JH, HOFFMAN GS, MERKEL PA et al.: A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001; 44: 912-20.
23. WEGENER'S GRANULOMATOSIS ETANERCEPT TRIAL (WGET) RESEARCH GROUP: Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351-61.
24. WGET RESEARCH GROUP: Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Control Clin Trials 2002; 23: 450-68.
25. STEGEMAN CA, TERVAERT JW, DE JONG PE, KALLENBERG CG: Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996; 335: 16-20.
26. WEIDNER S, GEUSS S, HAFEZI-RACHTI S, WONKA A, RUPPRECHT HD: ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant 2004; 19: 1403-11.
27. WESTMAN KW, SELGA D, ISBERG PE, BLADSTROM A, OLSSON H: High proteinase 3-anti-neutrophil cytoplasmic antibody (ANCA) level measured by the capture enzyme-linked immunosorbent assay method is associated with decreased patient survival in ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol 2003; 14: 2926-33.
28. HOGAN SL, NACHMAN PH, WILKMAN AS, JENNETTE JC, FALK RJ: Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7: 23-32.
29. LUQMANI RA, EXLEY AR, KITAS GD, BACON PA: Disease assessment and management of the vasculitides. Baillieres Clin Rheumatol 1997; 11: 423-46.
30. KEOGH KA, YTTERBERG SR, FERVENZA FC, CARLSON KA, SCHROEDER DR, SPECKS U: Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173: 180-7.
31. SCHMITT WH, HAGEN EC, NEUMANN I, NOWACK R, FLORES-SUAREZ LF, van der WOUDE FJ: Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004; 65: 1440-8.
32. METZLER C, FINK C, LAMPRECHT P, GROSS WL, REINHOLD-KELLER E: Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 2004; 43: 315-20.
33. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
34. PREVOO ML, van't HOF MA, KUPER HH, van LEEUWEN MA, van de PUTTE LB, van RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
35. GRIGOR C, CAPELL H, STIRLING A et al.: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263-9.
36. GUILLEVIN L, CORDIER JF, LHOTE F et al.: A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40: 2187-98.
37. HAUBITZ M, SCHELLONG S, GOBEL U et al.: Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998; 41: 1835-44.
38. ADU D, PALL A, LUQMANI RA et al.: Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. Qjm 1997; 90: 401-9.
39. European therapeutic trials in ANCA-Associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. European Community Study Group on Clinical Trials in Systemic Vasculitis ECSYSVASTRIAL. Clin Exp Immunol 1995; 101 (Suppl. 1): 29-34.
40. GUILLEVIN L, LHOTE F, GAYRAUD M et al.: Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996 75: 17-28.
41. GUILLEVIN L, FAIN O, LHOTE F et al.: Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients. Arthritis Rheum 1992; 35: 208-15.
42. GASKIN G, JAYNE D: Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis. J Am Soc Nephrol 2002; 13: F-FC010.
43. EXLEY AR, BACON PA, LUQMANI RA et al.: Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997; 40: 371-80.
44. JAYNE DR, CHAPEL H, ADU D et al.: Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Qjm 2000; 93: 433-9.
45. MUKHTYAR C, LUQMANI R: Current state of tumour necrosis factor (alpha) blockade in Wegener's granulomatosis. Ann Rheum Dis 2005; 64 (Suppl. 4): iv31-6.
46. KEOGH KA, WYLAM ME, STONE JH, SPECKS U: Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 262-8.
47. SLOT MC, TERVAERT JW, BOOMSMA MM, STEGEMAN CA: Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 2004; 51: 269-73.
48. GIRARD T, MAHR A, NOEL LH et al.: Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology (Oxford) 2001; 40: 147-51.
49. STEGEMAN CA, TERVAERT JW, SLUITER WJ, MANSON WL, de JONG PE, KALLENBERG CG: Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120: 12-7.
50. BOOMSMA MM, BIJL M, STEGEMAN CA, KALLENBERG CG, HOFFMAN GS, TERVAERT JW: Patients' perceptions of the effects of systemic lupus erythematosus on health, function, income, and interpersonal relationships: a comparison with Wegener's granulomatosis. Arthritis Rheum 2002; 47: 196-201.
51. BRIJKER F, MAGEE CC, TERVAERT JW, O'NEILL S, WALSHE JJ: Outcome analysis of patients with vasculitis associated with anti-neutrophil cytoplasmic antibodies. Clin Nephrol 1999; 52: 344-51.
52. KOLDINGSNES W, NOSSENT H: Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology (Oxford) 2002; 41: 572-81.
53. EXLEY AR, CARRUTHERS DM, LUQMANI RA et al.: Damage occurs early in systemic vasculitis and is an index of outcome. Qjm 1997; 90: 391-9.
54. BOOTH AD, ALMOND MK, BURNS A et al.: Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003; 41: 776-84.
55. GORDON M, LUQMANI RA, ADU D et al.: Relapses in patients with a systemic vasculitis. Q J Med 1993; 86: 779-89.
56. REINHOLD-KELLER E, FINK CO, HERLYN K, GROSS WL, de GROOT K: High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002; 47: 326-32.